2CB-Ind is a conformationally-restricted derivative of the phenethylamine hallucinogen 2C-B which was developed by David E. Nichols and colleagues. It acts as a moderately potent and selective agonist for the 5-HT<sub>2A</sub> and 5-HT<sub>2C</sub> receptors, but unlike the corresponding benzocyclobutene derivative TCB-2 which is considerably more potent than the parent compound 2C-B, 2CB-Ind is several times weaker, with racemic 2CB-Ind having a K<sub>i</sub> of 47nM at the human 5-HT<sub>2A</sub> receptor, only slightly more potent than the mescaline analogue (R)-jimscaline.